Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Marck Biosciences, a manufacturer of sterile liquids pharmaceutical dosages, has acquired a large volume injectible facility of Goa-based Ravish Infusion for INR54.7m.
Subscribe to our email newsletter
Marck Biosciences intends to increase its manufacturing capacity for large volume injectibles by over 33% by March 2011, The Business Standard reported.
The company plans to manufacture large volume parenterals with Euroheads at the Goa facility and market in South East Asia, East and West Africa and CIS countries.
Marck has recently come up with an IPO and plans to use the net proceeds to set up a sterile liquid manufacturing plant as per the WHO cGMP specifications, for fluid therapy and formulations and partly for corporate needs and partly for Issue expenses.
Marck Biosciences has also signed a memorandum of understanding (MoU) Paragon Steels (Gujarat Inject Kerala Limited) for purchase of its injectibles equipment for INR15m, which the company intends to set up at the Goa facility.
The Business Standard has quoted Marck Biosciences MD Bhavesh Patel as saying that the acquisitions will help the company expand capacity to meet the growing demand.
"With these two acquisitions, the total capacity for large volume injectibles will increase by 20 million bottles per year," Patel said.